Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Dianna Riall"'
Autor:
Yan Xing, Nancy U. Lin, Matthew A. Maurer, Huiqin Chen, Armeen Mahvash, Aysegul Sahin, Argun Akcakanat, Yisheng Li, Vandana Abramson, Jennifer Litton, Mariana Chavez-MacGregor, Vicente Valero, Sarina A. Piha-Paul, David Hong, Kim-Anh Do, Emily Tarco, Dianna Riall, Agda Karina Eterovic, Gerburg M. Wulf, Lewis C. Cantley, Gordon B. Mills, L. Austin Doyle, Eric Winer, Gabriel N. Hortobagyi, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-12 (2019)
Abstract Background The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations and PTEN loss in breast cancer. We conducted a phase II trial with an allosteric AKT inhibitor MK-2206 in patients with advanced breast cancer who had tumors with
Externí odkaz:
https://doaj.org/article/3eaaeb80b88d4c81acd24e596bc7212d
Autor:
Lewis C. Cantley, Vicente Valero, Nan Lin, Argun Akcakanat, Gerburg M. Wulf, Kim Anh Do, Matthew A. Maurer, Armeen Mahvash, Yisheng Li, Agda Karina Eterovic, Emily Tarco, Yan Xing, Gordon B. Mills, Gabriel N. Hortobagyi, Mariana Chavez-MacGregor, Eric P. Winer, Dianna Riall, L. Austin Doyle, David S. Hong, Aysegul A. Sahin, Ana M. Gonzalez-Angulo, Huiqin Chen, Vandana G. Abramson, Sarina Anne Piha-Paul, Funda Meric-Bernstam, Jennifer K. Litton
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-12 (2019)
Breast Cancer Research : BCR
Breast Cancer Research : BCR
Background The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations and PTEN loss in breast cancer. We conducted a phase II trial with an allosteric AKT inhibitor MK-2206 in patients with advanced breast cancer who had tumors with PIK3CA/AK
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51f8826e3866507335c07c8bca2ea935
https://doi.org/10.1186/s13058-019-1154-8
https://doi.org/10.1186/s13058-019-1154-8
Autor:
L. Austin Doyle, Funda Meric-Bernstam, Mathew S Mauer, Kim Anh Do, Emily Tarco, Karina Eterovic, Lewis C. Cantley, Ana M. Gonzalez-Angulo, Gordon B. Mills, Mariana Chavez-McGregor, Gabriel N. Hortobagyi, Armeen Mahvash, Eric P. Winer, Argun Akcakanat, Dianna Riall, David S. Hong, Sarina Anne Piha-Paul, Jennifer K. Litton, Yan Xing, Vandana Abraham, Nan Lin, Vicente Valero, Yisheng Li, Huiqin Chen, Aysegul A. Sahin
Publikováno v:
Molecular Cancer Research. 18:B24-B24
Background: The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations and PTEN loss in breast cancer. We conducted a phase II trial with an allosteric AKT Inhibitor MK-2206 in patients with advanced breast cancer who had tumors with PIK3CA/A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::669226a5483cd93b49872e7e725312bb
https://doi.org/10.1158/1557-3125.pi3k-mtor18-b24
https://doi.org/10.1158/1557-3125.pi3k-mtor18-b24